Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors

Jennifer K. Matsui; Haley K. Perlow; Rohit K. Raj; Ansel P. Nalin; Eric J. Lehrer; Rupesh Kotecha; Daniel M. Trifiletti; Shearwood McClelland; Kari Kendra; Nicole Williams; Dwight H. Owen; Carolyn J. Presley; Evan M. Thomas; Sasha J. Beyer; Dukagjin M. Blakaj; Manmeet S. Ahluwalia; Raju R. Raval; Joshua D. Palmer

doi:10.3390/biomedicines10092211

Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors

Jennifer K. Matsui, Haley K. Perlow, Rohit K. Raj, Ansel P. Nalin, Eric J. Lehrer, Rupesh Kotecha, Daniel M. Trifiletti, Shearwood McClelland, Kari Kendra, Nicole Williams, Dwight H. Owen, Carolyn J. Presley, Evan M. Thomas, Sasha J. Beyer, Dukagjin M. Blakaj, Manmeet S. Ahluwalia, Raju R. Raval, Joshua D. Palmer

Radiation Oncology

Research output: Contribution to journal › Review article › peer-review

Abstract

Brain metastases are a devastating sequela of common primary cancers (e.g., lung, breast, and skin) and have limited effective therapeutic options. Previously, systemic chemotherapy failed to demonstrate significant benefit in patients with brain metastases, but in recent decades, targeted therapies and more recently immune checkpoint inhibitors (ICIs) have yielded promising results in preclinical and clinical studies. Furthermore, there is significant interest in harnessing the immunomodulatory effects of radiotherapy (RT) to synergize with ICIs. Herein, we discuss studies evaluating the impact of RT dose and fractionation on the immune response, early studies supporting the synergistic interaction between RT and ICIs, and ongoing clinical trials assessing the benefit of combination therapy in patients with brain metastases.

Original language	English (US)
Article number	2211
Journal	Biomedicines
Volume	10
Issue number	9
DOIs	https://doi.org/10.3390/biomedicines10092211
State	Published - Sep 2022

Keywords

brain metastases
immune checkpoint inhibitors
immunoradiotherapy
radiation therapy
radiotherapy
systemic therapy

ASJC Scopus subject areas

Medicine (miscellaneous)
General Biochemistry, Genetics and Molecular Biology

Access to Document

10.3390/biomedicines10092211

Cite this

Matsui, J. K., Perlow, H. K., Raj, R. K., Nalin, A. P., Lehrer, E. J., Kotecha, R., Trifiletti, D. M., McClelland, S., Kendra, K., Williams, N., Owen, D. H., Presley, C. J., Thomas, E. M., Beyer, S. J., Blakaj, D. M., Ahluwalia, M. S., Raval, R. R., & Palmer, J. D. (2022). Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors. Biomedicines, 10(9), Article 2211. https://doi.org/10.3390/biomedicines10092211

Matsui, JK, Perlow, HK, Raj, RK, Nalin, AP, Lehrer, EJ, Kotecha, R, Trifiletti, DM, McClelland, S, Kendra, K, Williams, N, Owen, DH, Presley, CJ, Thomas, EM, Beyer, SJ, Blakaj, DM, Ahluwalia, MS, Raval, RR & Palmer, JD 2022, 'Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors', Biomedicines, vol. 10, no. 9, 2211. https://doi.org/10.3390/biomedicines10092211

@article{aa079a7aff344f4bb3464a09cc433743,

title = "Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors",

abstract = "Brain metastases are a devastating sequela of common primary cancers (e.g., lung, breast, and skin) and have limited effective therapeutic options. Previously, systemic chemotherapy failed to demonstrate significant benefit in patients with brain metastases, but in recent decades, targeted therapies and more recently immune checkpoint inhibitors (ICIs) have yielded promising results in preclinical and clinical studies. Furthermore, there is significant interest in harnessing the immunomodulatory effects of radiotherapy (RT) to synergize with ICIs. Herein, we discuss studies evaluating the impact of RT dose and fractionation on the immune response, early studies supporting the synergistic interaction between RT and ICIs, and ongoing clinical trials assessing the benefit of combination therapy in patients with brain metastases.",

keywords = "brain metastases, immune checkpoint inhibitors, immunoradiotherapy, radiation therapy, radiotherapy, systemic therapy",

author = "Matsui, {Jennifer K.} and Perlow, {Haley K.} and Raj, {Rohit K.} and Nalin, {Ansel P.} and Lehrer, {Eric J.} and Rupesh Kotecha and Trifiletti, {Daniel M.} and Shearwood McClelland and Kari Kendra and Nicole Williams and Owen, {Dwight H.} and Presley, {Carolyn J.} and Thomas, {Evan M.} and Beyer, {Sasha J.} and Blakaj, {Dukagjin M.} and Ahluwalia, {Manmeet S.} and Raval, {Raju R.} and Palmer, {Joshua D.}",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

month = sep,

doi = "10.3390/biomedicines10092211",

language = "English (US)",

volume = "10",

journal = "Biomedicines",

issn = "2227-9059",

publisher = "MDPI AG",

number = "9",

}

TY - JOUR

T1 - Treatment of Brain Metastases

T2 - The Synergy of Radiotherapy and Immune Checkpoint Inhibitors

AU - Matsui, Jennifer K.

AU - Perlow, Haley K.

AU - Raj, Rohit K.

AU - Nalin, Ansel P.

AU - Lehrer, Eric J.

AU - Kotecha, Rupesh

AU - Trifiletti, Daniel M.

AU - McClelland, Shearwood

AU - Kendra, Kari

AU - Williams, Nicole

AU - Owen, Dwight H.

AU - Presley, Carolyn J.

AU - Thomas, Evan M.

AU - Beyer, Sasha J.

AU - Blakaj, Dukagjin M.

AU - Ahluwalia, Manmeet S.

AU - Raval, Raju R.

AU - Palmer, Joshua D.

PY - 2022/9

Y1 - 2022/9

N2 - Brain metastases are a devastating sequela of common primary cancers (e.g., lung, breast, and skin) and have limited effective therapeutic options. Previously, systemic chemotherapy failed to demonstrate significant benefit in patients with brain metastases, but in recent decades, targeted therapies and more recently immune checkpoint inhibitors (ICIs) have yielded promising results in preclinical and clinical studies. Furthermore, there is significant interest in harnessing the immunomodulatory effects of radiotherapy (RT) to synergize with ICIs. Herein, we discuss studies evaluating the impact of RT dose and fractionation on the immune response, early studies supporting the synergistic interaction between RT and ICIs, and ongoing clinical trials assessing the benefit of combination therapy in patients with brain metastases.

AB - Brain metastases are a devastating sequela of common primary cancers (e.g., lung, breast, and skin) and have limited effective therapeutic options. Previously, systemic chemotherapy failed to demonstrate significant benefit in patients with brain metastases, but in recent decades, targeted therapies and more recently immune checkpoint inhibitors (ICIs) have yielded promising results in preclinical and clinical studies. Furthermore, there is significant interest in harnessing the immunomodulatory effects of radiotherapy (RT) to synergize with ICIs. Herein, we discuss studies evaluating the impact of RT dose and fractionation on the immune response, early studies supporting the synergistic interaction between RT and ICIs, and ongoing clinical trials assessing the benefit of combination therapy in patients with brain metastases.

KW - brain metastases

KW - immune checkpoint inhibitors

KW - immunoradiotherapy

KW - radiation therapy

KW - radiotherapy

KW - systemic therapy

UR - http://www.scopus.com/inward/record.url?scp=85138634425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85138634425&partnerID=8YFLogxK

U2 - 10.3390/biomedicines10092211

DO - 10.3390/biomedicines10092211

M3 - Review article

AN - SCOPUS:85138634425

SN - 2227-9059

VL - 10

JO - Biomedicines

JF - Biomedicines

IS - 9

M1 - 2211

ER -

Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this